CYRX

AI MemoPost-earnings T+1

CryoPort

As of 2026-05-04/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Customer approval cadence and clinical-program conversion remain the main external demand lever • 2026-12-31

Base target: $12 / p=45% prob

Biggest risk

This is still a low-coverage T+1 earnings follow-up with no trustworthy post-print analyst target-change or estimate-revision set confirmed from the checked sources. Cryoport also remains loss-making, the available peer set is mostly contextual rather than directly comparable, and the thesis still depends on customer CGT activity plus execution on new facilities rather than a fully proven self-funding operating model. [#PR-2026-05-04]

Invalidation

Break below $9 or thesis failure.

What would change my mind?

The post-earnings company release was materially better than the pre-print monitoring setup: revenue growth accelerated, commercial CGT and services trends stayed strong, adjusted EBITDA improved year over year, and management raised FY26 revenue guidance to $192 million-$196 million from $190 million-$194 million. That supports a modestly stronger positive bias than the April 28, 2026 baseline. [#PR-2026-05-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-05-04

Base target

$12

p=45%

Bull target

$14

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 revenue growth, EBITDA improvement, and raised FY26 guide reset the near-term earnings setup
Cash runway and 2026 facility launches are the distinct long-horizon financing and execution test
The post-earnings company release was materially better than the pre-print monitoring setup: revenue growth accelerated, commercial CGT and services trends stayed strong, adjusted EBITDA improved year over year, and management raised FY26 revenue guidance to $192 million-$196 million from $190 million-$194 million.

BearKey bullets

Cryoport remains loss-making despite EBITDA improvement, so any growth slowdown could delay the pathway to profitability.
Demand is still partly tethered to customer CGT approvals, filings, and program progression, which Cryoport does not control directly.
Execution risk remains around the planned Q3 2026 Paris BioServices launch and Q4 2026 Santa Ana opening.

WatchKey bullets

Customer approval cadence and clinical-program conversion remain the main external demand lever

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $12 (p=45%)

Target spread vs base: +17% / -29%

Scenario probabilities

Bull Target: $14 (p=30%)Base Target: $12 (p=45%)Bear Target: $9 (p=25%)

Commentary

Primary-source tone turned more constructive on May 4, 2026 because Cryoport paired a revenue beat-versus-prior internal trajectory with a guidance raise and better adjusted EBITDA. However, this remains a tentative monitoring-style earnings update rather than a standard-conviction report: regular-session price data available at 20:05 UTC on May 4 showed CYRX at $10.19 versus the $10.35 May 1 anchor, which does not provide a clean post-release reaction signal, no reliable post-print analyst revision set was confirmed from the checked sources, and the packet-listed peers are mostly contextual rather than direct operating comparators. Headline buzz is medium because the earnings release is clearly material, but coverage remains thin.

As of 2026-05-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 revenue growth, EBITDA improvement, and raised FY26 guide reset the near-term earnings setup
Cash runway and 2026 facility launches are the distinct long-horizon financing and execution test

Scenarios

Bull Target (Scenario probability)

$14 / p=30% prob

Base Target (Scenario probability)

$12 / p=45% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-05-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.34

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Customer approval cadence and clinical-program conversion remain the main external demand lever
Cryoport said it supported 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026, after previously guiding to multiple 2026 BLA/MAA filings and approvals. Because Cryoport sells infrastructure and services into the CGT ecosystem, customer regulatory wins and late-stage program conversions remain a real revenue driver even though they are not company-owned drug catalysts. [#PR-2026-05-04] [#8-K-2026-03-03]
Prob 65.00% • Move 8.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Q1 2026 revenue growth, EBITDA improvement, and raised FY26 guide reset the near-term earnings setup
2026-05-04
Cryoport reported Q1 2026 revenue of $47.8 million, up 16% year over year, commercial CGT revenue up 26% to $9.1 million, adjusted EBITDA from continuing operations improving to negative $0.6 million from negative $2.8 million, and raised full-year 2026 revenue guidance to $192 million-$196 million from the prior $190 million-$194 million range. That is the clearest incremental positive change versus the prior monitoring thesis, but it is still a T+1 update with limited external revision data. [#PR-2026-05-04]
Prob 85% • Move 10% • Priced-in 60%

Long-term Catalysts

Months to a year

Cash runway and 2026 facility launches are the distinct long-horizon financing and execution test
2026-12-31
Management highlighted planned BioServices operations at the Paris Global Supply Chain Center in Q3 2026 and the planned opening of the Santa Ana Global Supply Chain Center in Q4 2026, while ending Q1 with $403.6 million of cash, cash equivalents, and short-term investments. For this non-therapeutic CGT infrastructure business, the long-horizon catalyst is not a drug readout; it is whether Cryoport can use its cash runway to fund the 2026 footprint expansion and convert those facilities into utilization, revenue growth, and margin progress without renewed financing pressure. [#PR-2026-05-04] [#10-K-2026-03-05]
Prob 58% • Move 10% • Priced-in 45%

Risks

Cryoport remains loss-making despite EBITDA improvement, so any growth slowdown could delay the pathway to profitability.
Demand is still partly tethered to customer CGT approvals, filings, and program progression, which Cryoport does not control directly.
Execution risk remains around the planned Q3 2026 Paris BioServices launch and Q4 2026 Santa Ana opening.
Immediate post-earnings analyst revision and market-reaction evidence was limited at T+1, which lowers conviction in how durable the re-rating can be.
The provided peer set lacks enough direct operating comparators, so relative valuation and sentiment read-throughs are weaker than in a standard-conviction report.

Peers

Symbol	Summary
MLAB	Packet-listed same-sector and similar-market-cap candidate, and the closest operating-adjacent comparator in the provided set because it is more tools-and-systems oriented than the therapeutic developers. It is still not a clean direct peer for Cryoport's CGT supply-chain, biostorage, and cryogenic-systems platform, so it should not drive valuation confidence.
AUTL	Packet-listed cell-therapy developer and useful mainly for CGT ecosystem sentiment, approval cadence, and event-volatility context. It is not a direct operating or valuation comp for Cryoport because Cryoport provides infrastructure and services rather than owning therapeutic programs.
PRTA	Packet-listed small-cap biotech candidate with relevance mostly to sector risk appetite. Business-model comparability to Cryoport remains weak, reinforcing that the peer set is contextual rather than a standard direct-comparator set.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-04

Loading AI feed…

Symbol

Summary

MLAB

Packet-listed same-sector and similar-market-cap candidate, and the closest operating-adjacent comparator in the provided set because it is more tools-and-systems oriented than the therapeutic developers. It is still not a clean direct peer for Cryoport's CGT supply-chain, biostorage, and cryogenic-systems platform, so it should not drive valuation confidence.

AUTL

Packet-listed cell-therapy developer and useful mainly for CGT ecosystem sentiment, approval cadence, and event-volatility context. It is not a direct operating or valuation comp for Cryoport because Cryoport provides infrastructure and services rather than owning therapeutic programs.

PRTA

Packet-listed small-cap biotech candidate with relevance mostly to sector risk appetite. Business-model comparability to Cryoport remains weak, reinforcing that the peer set is contextual rather than a standard direct-comparator set.